盐酸安罗替尼治疗晚期恶性肿瘤的安全性及有效性分析  

Safety and efficacy analysis of anlotinib in treatment of advanced malignant tumors

作　　者：杨雪晶[1] 宋东[1] 杨晓玲[1] 冯慧晶[1] 张俊萍[1] Yang Xuejing;Song Dong;Yang Xiaoling;Feng Huijing;Zhang Junping(Department of Oncology,Shanxi Academy of Medical Sciences,Shanxi Bethune Hospital,Taiyuan 030032,China)

机构地区：[1]山西医学科学院山西白求恩医院肿瘤中心,太原030032

出　　处：《肿瘤研究与临床》2020年第7期489-492,共4页Cancer Research and Clinic

摘　　要：目的探讨盐酸安罗替尼治疗晚期恶性肿瘤的安全性及有效性。方法回顾性分析2018年7月至2019年7月山西白求恩医院收治的65例经二线治疗失败的晚期恶性肿瘤患者临床资料,其中非小细胞肺癌32例,小细胞肺癌12例,卵巢癌15例,腹膜癌6例,分析其客观总缓解率(ORR)、疾病控制率(DCR)、无进展生存(PFS)时间及相关不良反应。结果非小细胞肺癌ORR为43.7%(14/32),DCR为68.8%(22/32);小细胞肺癌ORR为8.3%(1/12),DCR为25.0%(3/12);卵巢癌ORR为33.3%(5/15),DCR为73.3%(11/15);腹膜癌ORR为0(0/6),DCR为33.3%(2/6)。非小细胞肺癌中位PFS时间8.0个月(95%CI 6.2~9.8个月),小细胞肺癌中位PFS时间3.0个月(95%CI 1.9~4.1个月),卵巢癌中位PFS时间5.0个月(95%CI 3.1~6.9个月),腹膜癌中位PFS时间2.0个月(95%CI 0.0~5.6个月)。药物相关非血液学不良事件中,高血压最为常见,Ⅰ~Ⅱ级6例(9.2%),Ⅲ~Ⅳ级1例(1.5%);药物相关血液学不良事件中,血小板减少最为常见,Ⅰ~Ⅱ级8例(12.3%),Ⅲ~Ⅳ级1例(1.5%),所有患者未出现不能耐受的不良反应。结论盐酸安罗替尼治疗晚期恶性肿瘤,药物相关不良反应小、疗效确切,是晚期恶性肿瘤治疗的选择之一。Objective To investigate the safety and efficacy of anlotinib in treatment of advanced malignant tumors.Methods The clinical data of 65 patients with advanced malignant tumors after the failure of the second-line treatment in Shanxi Bethune Hospital from July 2018 to July 2019 were retrospectively analyzed,including 32 cases of non-small cell lung cancer,12 cases of small cell lung cancer,15 cases of ovarian cancer,and 6 cases of peritoneal cancer.The objective total remission rate(ORR),disease control rate(DCR),progression-free survival(PFS)time,and the related adverse events were also analyzed.Results ORR in non-small cell lung cancer group was 43.7%(14/32),DCR was 68.8%(22/32);ORR in small cell lung cancer group was 8.3%(1/12),and DCR was 25.0%(3/12).ORR in ovarian cancer group was 33.3%(5/15),DCR was 73.3%(11/15).In peritoneal carcinoma group,ORR was 0(0/6)and DCR was 33.3%(2/6).The median PFS time was 8.0 months(95%CI 6.2-9.8 months)in the non-small cell lung cancer group,3.0 months(95%CI 1.9-4.1 months)in the small cell lung cancer group,5.0 months(95%CI 3.1-6.9 months)in the ovarian cancer group,and 2.0 months(95%CI 0.0-5.6 months)in the peritoneal cancer group.Hypertension was the most common non-hematology-related adverse event,and there were 6 cases(9.2%)of gradeⅠ-Ⅱadverse event and 1 case(1.5%)of gradeⅢ-Ⅳadverse event.Among the hematology-related adverse events,thrombocytopenia was the most common,and there were 8 cases(12.3%)of gradeⅠ-Ⅱadverse event and 1 case(1.5%)of gradeⅢ-Ⅳadverse event.All patients could tolerate the adverse reactions.Conclusion Anlotinib is one of the options for the treatment of advanced malignant tumors,with mild drug-related adverse reactions and definite efficacy.

关 键 词：肿瘤 安罗替尼 治疗结果 不良反应 

分 类 号：R730.5[医药卫生—肿瘤]